The reproductive and developmental toxicology areas have undergone numerous changes in the 30 years since the thalidomide tragedy. It would be comforting if such changes have resulted in a greatly decreased likelihood that human conceptuses will develop malformations. However, there is little evidence that such testing has better enabled us to identify human reproductive or developmental toxicants. Although there may be justification for performing animal testing on drugs and pesticides, a simple acute toxicity test may be just as predictive as currently employed reproductive and developmental toxicity tests for other synthetic chemicals. Support for this premise is provided by comparing available acute toxicity information on many compounds, identified as (potential) human developmental or reproductive toxicants, with their respective likely human threshold doses. Acute LD50 values of other potential human reproductive or developmental toxicants, not documented as being a threat to humans, also were compared with their time-weighted averages or their lowest teratogenic dose in the same species. The data generated support the premise that most reproductive or developmental toxicants are a potential threat to humans only if exposure levels approach those that are lethal in the rat or mouse. In contrast, unequivocal evidence of developmental toxicity for drugs, such as thalidomide and isotretinoin, to which the human embryo is highly sensitive, were not apparent in the screens used now for routine developmental toxicology testing. Thus, requirements that all chemicals be tested for reproductive and developmental toxicity should await the development of testing methodology capable of better assessing human risk.
References
1.
1. Amann, R.P. (1982). Use of animal models for detecting specific alterations in reproduction. Fund. Appl. Toxicol.2, 13–26.
2.
2. Brent, R.L. (1988). Predicting teratogenic and reproductive risks in humans from exposure to various environmental agents using in vitro techniques and in vivo animal studies. Cong. Anom.28, S41–S55.
3.
3. Fraser, F.C. (1977). Relation of animal studies to the problem in man, in: Handbook of Teratology, J. G. Wilson and F. C. Fraser (eds). New York: Plenum Press, 1, 75–96.
4.
4. Hemminki, K., and Vineis, P. (1985). Extrapolation of the evidence on teratogenicity of chemicals between humans and experimental animals: Chemicals other than drugs. Teratogen Carcinogen Mutagen5, 251–318.
5.
5. Hill, R. (1983). Model systems and their predictive value in assessing teratogens. Fund. Appl. Toxicol.3, 229–232.
6.
6. Johnson, E.M. (1980). Screening for teratogenic potential: Are we asking the proper questions?. Teratology21, 259.
7.
7. Khera, K.S. (1984). Adverse effects in humans and animals of prenatal exposure to selected therapeutic drugs and estimation of embryo-fetal sensitivity of animals for human risk assessment. A review, in: Issues and Reviews in Teratology. H. Kalter (ed). New York: Plenum Publishing Corp., 2, 399–507.
8.
8. Oser, B.L. (1981). The rat as a model for human toxicological evaluation. J. Toxicol. Environ. Health8, 521–542.
9.
9. Schardein, J.L. (1988). Teratologic testing: Status and issues after two decades of evolution. Rev. Environ. Contam. Toxicol.102, 1–78.
10.
10. Weissman, A. (1990). What it takes to validate behavioral toxicology tests: A belated commentary on the collaborative behavioral teratology study. Neurotoxicol. Teratol.12, 497–501.
11.
11. Wilson, J.G. (1979). The evolution of teratology testing. Teratology20, 205–211.
12.
12. Koch, H.P. (1990) Comments on “proposed mechanismsof action in thalidomide embryopathy”. Teratology41, 243–244.
13.
13. Stephens, T.D. (1990). Response to “Comments on proposed mechanisms of action in thalidomide embryopathy”. Teratology41, 245–246.
14.
14. Johnson, E.M. (1981). Screening for teratogenic hazards: Nature of the problems. Annu. Rev. Pharmacol. Toxicol.21, 417–429.
15.
15. SUBCOMMITTEE ON FOOD TOXICOLOGY. (1980) Risk assessment, in: Risk Assessment/Safety Evaluation of Food Chemicals. Washington, DC: National Academic Press, pp. 4–12.
16.
16. Black, D.L., and Marks, T.A. (1992). A discussion of the role of maternal toxicity in assessing developmental toxicity in animals. Submitted to Reg. Toxicol. Pharmacol.
17.
17. Brent, R.L. (1972). Protecting the public from teratogenic and mutagenic hazards. J. Clin. Pharmacol.12, 61–70.
18.
18. Wilson, J.L. (1963). Testing of drugs. Pediatrics31, 154–155.
19.
19. Efron, E. (1984). The Apocalyptics: How Environmental Politics Controls What We Know About Cancer. New York: Simon and Schuster, Inc.
20.
20. Abelson, P.H. (1990). Testing for carcinogens with rodents. Science249, 1357.
21.
21. Ames, B.N., and Gold, L.S. (1989). Alar in apples. Science244, 755–757.
22.
22. Huber, P.W. (1987). Little risks and big fears. Reg. Toxicol. Pharmacol.7, 200–205.
24. Slovic, P. (1987). Perception of risk. Science236, 280–285.
25.
25. Brent, R.L. (1964). Drug testing in animals for teratogenic effects: Thalidomide in the pregnant rat. J. Pediatr.64, 762–770.
26.
26. Johnson, E.M. (1984). A prioritization and biological decision tree for developmental toxicity safety evaluations. J. Am. Coll. Toxicol.3, 141–147.
27.
27. Johnson, E.M. (1987). A tier system for developmental toxicity evaluations based on considerations of exposure and effect relationships. Teratology35, 405–427.
28.
28. Schardein, J.L., and Keller, K.A. (1989). Potential human developmental toxicants and the role of animal testing in their identification and characterization. CRC Crit. Rev. Toxicol.19, 251–339.
29.
29. Sweet, D. V. (ed.) (1987). Registry of Toxic Effects of Chemical Substances. 1985–1986 Edition. Washington, DC: U.S. Government Printing Office.
30.
30. Budavari, S., O'neil, M.J., Smith, A., and Heckelman, P.E. (eds.) (1989). The Merck Index. An Encyclopedia of Chemicals, Drugs and Biologicals, 11th ed.Rahway, NJ: Merck & Co., Inc..
31.
31. Shepard, T.H. (1989). Catalog of Teratogenic Agents, 6th ed.Baltimore, MD: The Johns Hopkins University Press.
32.
32. Kizer, K.W., Warriner, T.E., and Book, S. A. (1988). Sound science in the implementation of public policy, a case report on California's Proposition 65. JAMA260, 951–955.
33.
33. Marks, T.A., Ledoux, T.A., and Moore, J.A. (1982). Teratogenicity of a commercial xylene mixture in the mouse. J. Toxicol. Environ. Health9, 97–105.
34.
34. Rosa, F.W., Wilk, A.L., and Kelsey, F.O. (1986). Teratogen update: Vitamin A congeners. Teratology33, 355–364.
35.
35. Physicians Desk Reference, 45th ed. (1991). Oradell, NJ: Medical Economics Co., Inc., pp. 1815–1817.
38. Black, D.L., and Marks, T.A. (1986). Inconsistent use of terminology in animal developmental toxicology studies: A discussion. Teratology33, 333–338.
39.
39. Collins, T.F.X., Welsh, J.J., Black, T.N., and Collins, E.V. (1981). A study of the teratogenic potential of caffeine given by oral intubation to rats. Reg. Toxicol. Pharmacol.1, 355–378.
40.
40. Dews, P., Grice, H.C., Neims, A., Wilson, J., and Wurtman, R. (1984). Report of fourth international caffeine workshop. Athens, 1982. Fd. Chem. Toxicol.22, 163–169.
41.
41. Brown, N.A., and Scialli, A.R. (eds). (1987). Update on caffeine, in: Reproductive Toxicology. A Medical Letter on Environmental Hazards to Reproduction. Washington, DC: Reproductive Toxicology Center, 6, 13–18.
42.
42. Dalvi, R.R. (1986). Acute and chronic toxicity of caffeine: A review. Vet. Hum. Toxicol.28, 144–150.
43.
43. Palm, P.E., Arnold, E.P., Rochwall, P.C., Leyczek, J.C., Teague, K.W., and Kensler, C.J. (1978). Evaluation of the teratogenic potential of fresh-brewed coffee and caffeine in the rat. Toxicol. Appl. Pharmacol.44, 1–16.
44.
44. Morris, M.B., and Weinstein, L. (1981). Caffeine and the fetus: Is trouble brewing? Am. J. Obstet. Gynecol.140, 607–610.
45.
45. Hart, E.R. (1947). The toxicity and analgetic potency of salicylamide and certain of its derivatives as compared with established analgetic-antipyretic drugs. J. Pharmacol. Expl. Ther.89, 205–209.
46.
46. Loosli, R., Loustalog, P., Schalch, W.R., Sievers, K., and Stenger, E.G. (1964). Joint study in teratogenicity research. Preliminary communication. Proc. Eur. Soc. Study Drug Toxic.4, 214–216.
47.
47. Flower, R.J., Moncada, S., and Vane, J.R. (1985). Analgesic-antipyretics and anti-inflammatory agents; drugs employed in the treatment of gout, in: Goodman and Gilman's The Pharmacological Basis of Therapeutics, 7th ed., A. G. Gilman, L. S. Goodman, T. W. Rall, and F. Murad (eds). New York, Macmillan, pp. 674–715.
48.
48. McNIEL, J.R. (1973). The possible teratogenic effect of salicylates on the developing fetus. Brief summaries of eight suggestive cases. Clin. Pediatr.12, 347–350.
49.
49. Mankes, R.F., Rosenblum, I., Benitz, K.F., Lefevre, R., and Abraham, R. (1982). Teratogenic and reproductive effects of ethanol in Long-Evans rats. J. Toxicol. Environ. Health10, 267–276.
50.
50. Wiberg, C.S., Trenholm, H.L., and Coldwell, B.B. (1970). Increased ethanol toxicity in old rats: Changes in LD50 in vivo and in vitro metabolism, and liver alcohol dehydrogenase activity. Toxicol. Appl. Pharmacol.16, 718–727.
51.
51. Streissguth, A.P., Landesman-Dwyer, S., Martin, J.C., and Smith, D.W. (1980). Teratogenic effects of alcohol in humans and laboratory animals. Science209, 353–361.
52.
52. Kamm, J.J. (1982). Toxicology, carcinogenicity, and teratogenicity of some orally administered steroids. J. Am. Acad. Dermatol.6, 652–659.
53.
53. Neuhaus, G., and Ibe, K. (1961). Survival following overdose of thalidomide. Dis. Nerv. System22, 52–53.
54.
54. King, C.T.G., and Kendrick, F.J. (1962). Teratogenic effects of thalidomide in the Sprague-Dawley rat. Lancet2, 1116.
55.
55. Staples, R.E., and Holtkamp, D.E. (1963). Effects of parental thalidomide treatment on gestation and fetal development. Exp. Mol. Pathol. (suppl.)2, 81–106.
56.
56. Homburger, F., Chaube, S., Eppenberger, M., Bogdonoff, P.D., and Nixon, C.W. (1965). Susceptibility of certain inbred strains of hamsters to teratogenic effects of thalidomide. Toxicol. Appl. Pharmacol.7, 686–693.
57.
57. Wuest, H.M., Sigg, E.B., and Fratta, I. (1964). Pharmacological properties and teratogenic action of 2-[hexahy-drophthalimido] glutamide and 2-phthalimido-N-methylglutarimide. Life Sci.3, 721–724.
58.
58. Di Paolo, J.A. (1963). Congenital malformation in strain A mice. JAMA183, 139–141.
59.
59. Ames, B.N., Profet, M., and Gold, L.S. (1990). Dietary pesticides (99.99% all natural). Proc. Natl. Acad. Sci. USA87, 7777–7781.
60.
60. Cohen, S.M., and Ellwein, L.B. (1990). Cell proliferation in carcinogenesis. Science249, 1007–1011.
61.
61. Higginson, J. (1987). Everything is a carcinogen. Reg. Toxicol. Pharmacol.7, 89–95.
62.
62. Johannsen, F.R. (1990). Risk assessment of carcinogenic and noncarcinogenic chemicals. Crit. Rev. Toxicol.20, 341–367.
63.
63. Young, F.E. (1987). Risk assessment: The convergence of science and the law. Reg. Toxicol. Pharmacol.7, 179–184.
64.
64. Wilson, J.D. (1987). A dose-response curve for Yusho syndrome. Reg. Toxicol. Pharmacol.7, 364–369.
65.
65. Marks, T.A., Kimmel, G.L., and Staples, R.E. (1981). Influence of symmetrical polychlorinated biphenyl isomers on embryo and fetal development in mice. I. Teratogenicity of 3,3′,4,4′,5,′-hexachlorobiphenyl. Toxicol. Appl. Pharmacol.61, 269–276.
66.
66. Marks, T.A., Kimmel, G.L., and Staples, R.E. (1989). Influence of symmetrical polychlorinated biphenyl isomers on embryo and fetal development in mice. II. Comparisons of 4,4′-dichlorobiphenyl, 3,3′,4,4′-tetrachlorobiphenyl, 3,3′,5,5′-tetrachlorobiphenol and 3,3′,4,4′-tetramethylbiphenyl. Fund. Appl. Toxicol.13, 681–693.
67.
67. Courtney, K.D., and Moore, J.A. (1971). Teratology studies with 2,4,5-trichlorophenoxyacetic acid and 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol. Appl. Pharmacol.20, 396–403.
68.
68. Safe, S. (1984). Polychlorinated biphenyls (PCBs) and polybrominated biphenyls (PBBs): Biochemistry, toxicology, and mechanism of action. CRC Crit. Rev. Toxicol.13, 319–395.
69.
69. Kuratsune, M., Yoshimura, T., Matsuzaka, J., and Yamaguchi, A. (1972). Epidemiologic study on Yusho, a poisoning caused by ingestion of rice oil contaminated with a commercial brand of polychlorinated biphenyls. Environ. Health Perspect.1, 119–128.
70.
70. Yamashita, F. (1977). Clinical features of polychlorobiphenyls (PCB)-induced fetopathy. Paediatrician6, 20–27.
71.
71. Yamashita, F., and Hayashi, H. (1985). Fetal PCB syndrome: Clinical features, intrauterine growth retardation and possible alteration in calcium metabolism. Environ. Health Perspect.59, 41–45.
72.
72. Iarc (1979). Chlordecone. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans. 20, 67–81.
73.
73. IARC (1979). 1,2-Dibromo-3-Chloropropane. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans. 20, 83–96.
74.
74. Guzelian, P.S. (1982). Comparative toxicology of chlordecone (kepone) in humans and experimental animals. Annu. Rev. Pharmacol. Toxicol.22, 89–113.
75.
75. Martinez, J., Taylor, J.R., Dyck, P.J., Houff, S.A., and Isaacs, E. (1978). Chlordecone intoxication in man. II. Ultrastructure of peripheral nerves and skeletal muscle. Neurology28, 631–635.
76.
76. Whorton, D., Krauss, R.M., Marshall, S., and Milby, T.H. (1977). Infertility in male pesticide workers. Lancet2, 1259–1261.
77.
77. Kodama, J.K., and Dunlap, M.K. (1956). Toxicity of 1,2-dibromo-3-chloropropane. Fed. Proc.15, 448.
79. ANON. (1976). NIOSH recommends exposure level of one microgram per cubic meter. Occup. Saf. Health Rep.5, 1195.
80.
80. Cannon, S.B., Veazey, J.M., Jr., Jackson, R.S., et al. (1978). Epidemic kepone poisoning in chemical workers. Am. J. Epidemiol.107, 529–537.
81.
81. Larson, P.S., Egle, J.L., Jr., Hennigar, G.R., Lane, R.W., and Borzelleca, J.F. (1979). Acute, subchronic, and chronic toxicity of chlodecone. Toxicol. Appl. Pharmacol.48, 29–41.
82.
82. Cannon, S.B., and Kimbrough, R.D. (1979). Short-term chlordecone toxicity in rats including effects on reproduction, pathological organ changes and their reversibility. Toxicol. Appl. Pharmacol.47, 469–476.
83.
83. Eisele, J.W., and Reay, D.T. (1980). Deaths related to coffee enemas. JAMA244, 1608–1609.
85. Bertazzi, P.A., Zocchetti, C., Pesateri, A.C., Guercilena, A., Sanarico, M., and Radice, L. (1989). Ten-year mortality study of the population involved in the Seveso incident in 1976. Am. J. Epidemiol.129, 1187–1200.
86.
86. Kimbrough, R.D., Falk, H., Stehr, P., and Fries, G. (1984). Health implications of 2,3,7,8-tetrachlorodibenzo-dioxin (TCDD) contamination of residential soil. J. Toxicol. Environ. Health14, 47–93.
88. Zack, J.A., and Suskind, R.R. (1980). The mortality experience of workers exposed to tetrachlorodibenzodioxin in a trichlorophenol process accident. J. Occup. Med.22, 11–14.
89.
89. Gross, M.L. (1979). The dioxin issue. Science206, 327–328.
90.
90. Homberger, F., Reggiani, G., Sambeth, J., and Wipf, H.K. (1979). The Seveso accident: Its nature, extent and consequences. Ann. Occup. Hyg.22, 327–367.
91.
91. Pocchiari, F., Silano, V., and Zampieri, A. (1979). Human health effects from accidental release of tetrachlorodibenzo-p-dioxin (TCDD) at Seveso, Italy. Ann. NY Acad. Sci.320, 311–320.
92.
92. Ketchem, L.E. (1987). Lessons of Chernobyl: SNM members try to decontaminate world threatened by fallout. J. Nucl. Med.6, 933–942.
93.
93. Czeizel, A., and Rácz, J. (1990). Evaluation of drug intake during pregnancy in the Hungarian case-control surveillance of congenital anomalies. Teratology42, 505–512.
94.
94. Koren, G., Bologa, M., Long, D., Feldman, Y., and Shear, N.H. (1989). Perception of teratogenic risk by pregnant women exposed to drugs and chemicals during the first trimester. Am. J. Obstet. Gynecol.160, 1190–1194.
95.
95. Wilson, J.G. (1973). Principles of teratology, in: Environment and Birth Defects. New York: Academic Press, pp. 11–34.
96.
96. Hart, W.L., Reynolds, R.C., Krasavage, W.J., Ely, T.S., Bell, R.H., and Raleigh, R.L. (1988). Evaluation of developmental toxicity data: A discussion of some pertinent factors and a proposal. Risk Anal.8, 59–69.
